Recent researches for dual Aurora target inhibitors in antitumor field

Liu, Maoyu; Ju, Xueming; Zou, Jing; Shi, Jiangyou; Ge, Jia

doi:10.1016/j.ejmech.2020.112498

Cited by 3 publications

(1 citation statement)

References 111 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Abnormal cell differentiation is one of the biological characteristics of cancer. 1 During the process of benign lesions transforming to malignant tumors, the cells progressively acquiring the undifferentiated state by reversal of the differentiation signals is one of the critical changes. 2 The abnormal differentiation of tumor cells is a complex process involving multiple links, multiple steps, and multiple targets.…”

Section: Introductionmentioning

confidence: 99%

Relationship Between Infiltration of CD163+ TAMs, FoxP3+ Tregs, or CD66b+ TANs and Cell Differentiation in Colorectal Cancer Tissues

Wang¹,

Bai²,

Zhou³

et al. 2023

Turk J Gastroenterol

View full text Add to dashboard Cite

Background/Aims: There are many studies on immune cell infiltration in colorectal cancer, including FoxP3 + -regulatory T cells, CD66b + tumor-associated neutrophils, and CD163 + tumor-associated macrophages. These studies mainly focus on the relationship between cell infiltration and tumor progression, prognosis, and so on, while the relationship between tumor cell differentiation and cell infiltration is poorly understood. We aimed to explore the relationship between cell infiltration and tumor cell differentiation. Materials and Methods: The tissue microarray and immunohistochemistry were used to determine the infiltration of FoxP3 + -regulatory T cells, CD66b + tumor-associated neutrophils, and CD163 + tumor-associated macrophages in 673 colorectal cancer samples from the Second Affiliated Hospital, Wenzhou Medical University (2001-2009). Kruskal–Wallis test was used to assess the positive cell infiltration in colorectal cancer tissues with tumor cells of varying degrees of differentiation. Results: The number of CD163 + tumor-associated macrophages, FoxP3 + -regulatory T cells, and CD66b + tumor-associated neutrophils in colorectal cancer tissues was different, and the level of CD163 + tumor-associated macrophages was the highest while the level of FoxP3 + -regulatory T cells was the least. There were significant differences in the cell infiltration of colorectal cancer tissue cells with different levels of differentiation ( P < .05). The highest infiltration of CD163 + tumor-associated macrophages (154.07 ± 6.95) and FoxP3 + -regulatory T cells (20.14 ± 2.07) were in the poorly differentiated colorectal cancer tissues, while the higher infiltration of CD66b + tumor-associated neutrophils was in the moderately or well-differentiated colorectal cancer tissues (36.70 ± 1.10 and 36.09 ± 1.06, respectively). Conclusion: Infiltration of CD163 + tumor-associated macrophages, FoxP3 + -regulatory T cells, and CD66b + tumor-associated neutrophils in colorectal cancer tissues may be related to the differentiation of tumor cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Relationship Between Infiltration of CD163+ TAMs, FoxP3+ Tregs, or CD66b+ TANs and Cell Differentiation in Colorectal Cancer Tissues

Wang¹,

Bai²,

Zhou³

et al. 2023

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1

Fan

Zhang

Liu

et al. 2023

Bioorganic Chemistry

View full text Add to dashboard Cite

Current Status and Perspectives of Novel Radiopharmaceuticals with Heterologous Dual-targeted Functions: 2013–2023

Li,

Ruan,

Jiang

et al. 2024

J. Med. Chem.

View full text Add to dashboard Cite

Radiotracers provide molecular-and cellular-level information in a noninvasive manner and have become important tools for precision medicine. In particular, the successful clinical application of radioligand therapeutic (RLT) has further strengthened the role of nuclear medicine in clinical treatment. The complicated microenvironment of the lesion has rendered traditional single-targeted radiopharmaceuticals incapable of fully meeting the requirements. The design and development of dualtargeted and multitargeted radiopharmaceuticals have rapidly emerged. In recent years, significant progress has been made in the development of heterologous dual-targeted radiopharmaceuticals. This perspective aims to provide a comprehensive overview of the recent progress in these heterologous dual-targeted radiopharmaceuticals, with a special focus on the design of ligand structures, pharmacological properties, and preclinical and clinical evaluation. Furthermore, future directions are discussed from this perspective. ■ SIGNIFICANCEResearch on heterologous dual-targeted radiopharmaceuticals has become an important component of radiopharmaceutical development. This perspective explores recent applications and advances, systematically discusses the structural design, pharmacological properties, and preclinical and clinical evaluation of the most advanced heterologous dual-targeted radiopharmaceuticals. It highlights the advantages of the use of bioactive molecules obtained via this design strategy, and provides prospects for future strategies that may promote the development of heterologous dual-targeted radiopharmaceuticals.

show abstract

Recent researches for dual Aurora target inhibitors in antitumor field

Cited by 3 publications

References 111 publications

Relationship Between Infiltration of CD163+ TAMs, FoxP3+ Tregs, or CD66b+ TANs and Cell Differentiation in Colorectal Cancer Tissues

Relationship Between Infiltration of CD163+ TAMs, FoxP3+ Tregs, or CD66b+ TANs and Cell Differentiation in Colorectal Cancer Tissues

Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1

Current Status and Perspectives of Novel Radiopharmaceuticals with Heterologous Dual-targeted Functions: 2013–2023

Contact Info

Product

Resources

About